Loading…
PTGX
Protagonist Therapeutics, Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 74366E102
$139.53+1.05%Price as of Oct 23, 00:49 UTC · updated once a day, after the close
At a glance
Protagonist Therapeutics, Inc (PTGX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Newark, United States and has 141 employees. The company is worth $9.03B and trades at 134.2x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $46.02M in fiscal 2025, down 89.4% from the year before. It reported a net loss of $130.15M. The share price is 13.2% below its 52-week high of $160.81. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Stanley Druckenmiller (Duquesne Family Office), at $25.61M. In that quarter, 1 of them opened or added to the position. Over the last 30 days, company insiders sold $8.31M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $9.03B
- P/E
- 134.2x
- Forward P/E
- —
- P/B
- 10.7x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $1.04
- ROE
- 10.98%
- Profit margin
- 29.40%
- Revenue growth
- +3749.20%
- Beta
- 1.52
- 52-week high
- $160.81
- 52-week low
- $73.08
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +283.0% over 5Y.
today you would have $4,131.90▲ +313.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 10 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $87.34 | $38.60 | $22.93 | $10.91 | $34.20 | $20.16 | $7.05 | $6.73 | $20.80 | $21.99 | |
| P/E | — | — | 9.1x | — | — | — | — | — | — | — | — |
| P/S | 22.3x |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$17.45
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$25.26
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$16.42
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TWSTTwist Bioscience Corp | $135.47 | — | 19.0x | 0.00% | -29.59% | $8.98B |
| TXG10x Genomics, Inc. | $69.75 | — | 11.0x | 0.00% | -9.40% | $9.09B |
| CAICaris Life Sciences, Inc. | $31.71 | 19.1x | 15.1x | 0.00% | 20.13% | $8.96B |
| KYMRKymera Therapeutics, Inc. | $110.85 |
About the company
- 141
- Newark, United States